Brenda Iveson, 92, from North Yorkshire, had been told there was nothing more that could be done. Surgery was not viable. Neither was radiotherapy nor conventional chemotherapy. The size and location of her liver tumour, combined with her age and frailty, placed each of those options out of reach. What followed instead was a procedure that had never been performed in the UK in quite this way, and one that has since reduced her tumour by approximately 80 per cent.

The treatment, carried out at Leeds Teaching Hospitals NHS Trust, combined electrochemotherapy with robotic needle guidance. Electrochemotherapy itself is not entirely new. It works by delivering a low dose of chemotherapy alongside targeted electrical pulses, which increase the permeability of cancer cell membranes and allow the drugs to enter more effectively than they otherwise would. What distinguished this case was the addition of robotic assistance to guide needle placement around the tumour with a degree of precision that manual approaches cannot reliably achieve, particularly in complex liver cases where the margin for error is narrow.

The clinical significance of this lies partly in what the procedure does not do. It is non-thermal. Unlike conventional ablation techniques, which destroy tissue using heat, electrochemotherapy does not generate the thermal spread that makes treatment near blood vessels and bile ducts so hazardous. Brenda's tumour was located in one of those high-risk areas, where standard interventional approaches would have posed an unacceptable risk to the surrounding structures. The robotic guidance allowed clinicians to work in that space with a level of accuracy that made the procedure feasible where it would not otherwise have been.

The procedure was led by Professor Tze Min Wah, Research and Innovation Lead for the Interventional Oncology Programme at Leeds Teaching Hospitals NHS Trust and Professor of Interventional Radiology at the University of Leeds. Professor Wah described the development as opening up possibilities for patients whose tumours are in difficult locations or who are not suitable candidates for other treatments, noting that robotic guidance improves the precision of needle placement in ways that directly expand the range of cases that can be considered.

The procedure was not the work of a single team or department. Oncology specialists, radiologists, pharmacists and research staff all contributed to Brenda's care, from initial referral through to post-treatment follow-up. The electrochemotherapy technology itself was provided by industry partner IGEA, whose involvement reflects the kind of NHS-industry collaboration that has been increasingly necessary to bring emerging interventional tools into clinical practice.

Leeds Teaching Hospitals is currently the only NHS site in the United Kingdom participating in the RESPECT trial, a European research study sponsored by the Cardiovascular and Interventional Radiology Society of Europe. The trial is collecting data on the effectiveness and safety of electrochemotherapy for liver cancer, with a particular focus on its impact on survival rates, quality of life and pain management. Patients treated at Leeds are therefore contributing directly to a body of evidence that will inform how this approach is adopted, or not, across Europe.

The broader implications for NHS oncology are worth considering carefully. Leeds has established what it describes as a new specialist service, with the potential to extend access to patients across the country who have reached the limits of conventional treatment pathways. The direction of travel is clear: more precise, less invasive, and targeted at the patients who currently have the fewest options. Whether that ambition translates into national provision will depend on how the evidence from trials such as RESPECT develops, and on whether NHS England moves to commission the service more widely. For now, Leeds holds that ground alone.

‍